Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as C$1.15 and last traded at C$1.17, with a volume of 121921 shares trading hands. The stock had previously closed at C$1.18.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Trading Down 2.7 %

The firm’s fifty day moving average price is C$1.48 and its 200-day moving average price is C$1.41. The company has a market cap of C$84.55 million, a price-to-earnings ratio of -2.89 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.